Európai Unió - magyar - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkapto-purin-monohidrátot - leukémia, limfóma - daganatellenes szerek - a xaluprine felnőttek, serdülők és gyermekek akut lymphoblastic leukémia (all) kezelésére javallt.

Európai Unió - magyar - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 5.

Európai Unió - magyar - EMA (European Medicines Agency)

nova laboratories ireland limited - hidroxi- - anémia, sarlósejt - daganatellenes szerek - megelőzés, a vaso-elnyelő szövődmények a sarlósejtes betegség, a betegek több mint 2 év.

Európai Unió - magyar - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - az a / vietnam / 1194/2004 (h5n1) törzs influenzavírus-felületi antigénjei (hemagglutinin és neuraminidáz) - influenza, human; immunization; disease outbreaks - a vakcinák - aktív immunizálás az influenza a vírus h5n1 altípusa ellen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Európai Unió - magyar - EMA (European Medicines Agency)

nova laboratories ireland limited - azatioprin - graft visszautasítás - immunszuppresszánsok - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Európai Unió - magyar - EMA (European Medicines Agency)

novartis europharm limited - a vildagliptin, metformin-hidroklorid - diabetes mellitus, 2. típus - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5. és 5. sz. 1 a rendelkezésre álló adatokra a különböző kombinációk esetén).

Európai Unió - magyar - EMA (European Medicines Agency)

mallinckrodt pharmaceuticals ireland limited - humán fibrinogén, humán trombin - hemosztázis, sebészeti - antihaemorrhagiás - ahol a standard sebészi technikák elégtelenek, haemostasis javításáért kezelési módok. raplixa kell kombinálva kell használni jóváhagyott zselatin szivacs. raplixa jelzi, felnőtteknek 18 év felett.

Európai Unió - magyar - EMA (European Medicines Agency)

novartis europharm ltd. - aliszkiren - magas vérnyomás - a renin-angiotenzin rendszerre ható szerek - az esszenciális hipertónia kezelése.

Európai Unió - magyar - EMA (European Medicines Agency)

le vet beheer b.v.  - meloxikám - oxicams - lovak - gyulladás enyhítése és fájdalomcsillapítás mind akut, mind krónikus mozgásszervi betegségekben.

Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

meda pharma hungary kft. - mitoxantrone -